| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5457 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2832 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1710 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1366 | 2021 |
| T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial KJ Ewer, JR Barrett, S Belij-Rammerstorfer, H Sharpe, R Makinson, ... Nature medicine 27 (2), 270-278, 2021 | 620 | 2021 |
| Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses JR Barrett, S Belij-Rammerstorfer, C Dold, KJ Ewer, PM Folegatti, ... Nature medicine 27 (2), 279-288, 2021 | 345 | 2021 |
| Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ... The Lancet 398 (10304), 981-990, 2021 | 278 | 2021 |
| Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination AM Minassian, SE Silk, JR Barrett, CM Nielsen, K Miura, A Diouf, C Loos, ... Med 2 (6), 701-719. e19, 2021 | 121 | 2021 |
| A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice A Silva-Cayetano, WS Foster, S Innocentin, S Belij-Rammerstorfer, ... Med 2 (3), 243-262. e8, 2021 | 89 | 2021 |
| Overcoming symmetry mismatch in vaccine nanoassembly through spontaneous amidation R Rahikainen, P Rijal, TK Tan, HJ Wu, AMC Andersson, JR Barrett, ... Angewandte Chemie International Edition 60 (1), 321-330, 2021 | 68 | 2021 |
| Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding LC Walters, K Harlos, S Brackenridge, D Rozbesky, JR Barrett, V Jain, ... Nature communications 9 (1), 3137, 2018 | 66 | 2018 |
| Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells J Jin, RD Tarrant, EJ Bolam, P Angell-Manning, M Soegaard, ... npj Vaccines 3 (1), 32, 2018 | 61 | 2018 |
| Protein/AS01B vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors CM Nielsen, A Ogbe, I Pedroza-Pacheco, SE Doeleman, Y Chen, SE Silk, ... Cell Reports Medicine 2 (3), 2021 | 40 | 2021 |
| Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assembly AM Minassian, Y Themistocleous, SE Silk, JR Barrett, A Kemp, D Quinkert, ... JCI insight 6 (23), 2021 | 22 | 2021 |
| Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5. 1/AS01B malaria vaccine CM Nielsen, JR Barrett, C Davis, JK Fallon, C Goh, AR Michell, C Griffin, ... JCI insight 8 (2), 2023 | 17 | 2023 |
| Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection MM Hou, JR Barrett, Y Themistocleous, TA Rawlinson, A Diouf, ... Science translational medicine 15 (704), eadf1782, 2023 | 16 | 2023 |
| Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults SE Silk, WF Kalinga, IM Mtaka, NS Lilolime, M Mpina, F Milando, ... Med 4 (10), 668-686. e7, 2023 | 15 | 2023 |
| Combinatorial Tim‐3 and PD‐1 activity sustains antigen‐specific Th1 cell numbers during blood‐stage malaria RS Dookie, A Villegas‐Mendez, H Kroeze, JR Barrett, SJ Draper, ... Parasite immunology 42 (9), e12723, 2020 | 13 | 2020 |
| An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females NG Marchevsky, G Li, P Aley, SAC Clemens, JR Barrett, ... EBioMedicine 81, 2022 | 11 | 2022 |
| Impact of a blood-stage vaccine on Plasmodium vivax malaria MM Hou, JR Barrett, Y Themistocleous, TA Rawlinson, A Diouf, ... MedRxiv, 2022 | 11 | 2022 |
